進行性大腸直腸がんに対する断続的および継続的な緩和化学療法の比較:多センターランダム化試験
T S Maughan1, R D James, D J Kerr
1Department of Oncology, Velindre Hospital, Cardiff, UK.
Lancet (London, England)
|February 14, 2003
まとめ
進行した結腸直腸がんでは,12週間後に化学療法を中止し,進行を再開することは安全です. この中断化学療法のアプローチは,継続的な治療よりも毒性の少ない効果を示し,全生存率に有意な違いはありませんでした.
科学分野:
- 腫瘍学 腫瘍学
- クリニック・トライアル 臨床試験
- 胃腸がん 胃腸がん 胃腸がん
背景:
- 進行性大腸直腸がんの化学療法期間は,英国の臨床医によって異なります.
- 一貫した政策が欠如しているため,比較効果に関する研究が必要となる.
研究 の 目的:
- 進行した結腸直腸がんにおける連続化学療法と中断化学療法の効果を比較する.
- 2つの化学療法戦略の間の安全性と生存結果を評価するために.
主な方法:
- 進行した結腸直腸がんの患者は,特定の化学療法療法療法による12週間の治療後に反応または安定した状態で,ランダムに割り当てられました.
- 断続的なグループ:化学療法中断,進行時に再開. 継続グループ:進行まで化学療法.
主要な成果:
- 354人の患者が登録されました. 断続的な化学療法により,有毒性効果と重篤な有害事象が著しく減少しました.
- 断続的な化学療法群と継続的な化学療法群の間では,全生存期における明確な違いは観察されなかった.
- 断続的な治療を受けた患者のうち,計画通り再開した患者はわずか37%であった.
結論:
- 病気の進行が明らかな生存効果を提供しないまで,無期限に化学療法を継続する.
- 12週間後に化学療法を中止し,進行時に再開することは,化学反応に敏感な進行性結腸直腸癌の安全な戦略です.
- 断続的な化学療法は,好ましい安全性プロファイルを示しています.
さらに関連する動画
06:28E-Patient Counseling Trial (E-PACO): Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
Published on: August 1, 2019
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
関連する概念動画
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:20Comparing the Survival Analysis of Two or More Groups
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...